CONSULTATION AND REPORTS. 4.1 Sponsor's designated representative for consultation and communications with the Principal Investigator shall be Sponsor's Vice President of Research and Development or such other person as Sponsor may from time to time designate in writing to University and the Principal Investigator ("Designated Representative"). 4.2 During the Term of the Agreement, Sponsor's representatives may consult informally with University's representatives regarding the project, both personally and by telephone. Access to work carried on in University laboratories in the course of these investigations shall be entirely under the control of University personnel but shall be made available to Sponsor's representatives on a reasonable basis. 4.3 The Principal Investigator will make up to two (2) oral reports each year as requested by Sponsor's Designated Representative. In addition, at the conclusion of each calendar quarter and each year, the Principal Investigator shall submit to Sponsor a written report summarizing the work. The Principal Investigator shall also submit a comprehensive final report within one hundred twenty (120) days of termination of the Agreement which shall contain, but which need not be limited to, the following information: a. A summary of expenses of the Research Program; and, b. A report of the activities undertaken and accomplishments achieved by the University under the Research Program. [*#*] CONFIDENTIAL TREATMENT REQUESTED
Appears in 2 contracts
Samples: Patent and Technology License Agreement (Myogen Inc), Patent and Technology License Agreement (Myogen Inc)
CONSULTATION AND REPORTS. 4.1 5.1 Sponsor's designated representative for consultation and communications with the Principal Investigator shall be Sponsor's Xxxx W.M.M. Terstappen, M.D., Ph.D., Senior Vice President of Research and Development Development, or such other person as Sponsor may from time to time designate in writing to University and the Principal Investigator ("Designated Representative").
4.2 5.2 During the Term of the Agreement, Sponsor's representatives may consult informally with University's representatives regarding the project, both personally and by telephone. Access to work carried on in University laboratories in the course of these investigations shall be entirely under the control of University personnel but shall be made available to Sponsor's representatives on a reasonable basis.. **
4.3 5.3 The Principal Investigator will make up to two (2) oral reports each year at reasonable intervals as requested by Sponsor's Designated Representative. In addition, at At the conclusion of each calendar quarter and each year, the Principal Investigator shall submit to Sponsor a written report summarizing the work. The Principal Investigator shall also submit a comprehensive final report within one hundred twenty (120) days of termination of the Agreement which shall contain, but which need not be limited to, the following information:
a. A summary of expenses of the Research Program; and,.
b. A report of the activities undertaken and accomplishments achieved by the University under the Research Program. [*#*] CONFIDENTIAL TREATMENT REQUESTED.
Appears in 2 contracts
Samples: Exclusive License Agreement (Immunicon Corp), Exclusive License Agreement (Immunicon Corp)
CONSULTATION AND REPORTS. 4.1 Sponsor's designated representative for consultation and communications with the Principal Investigator shall be the Sponsor's Vice President of Research and Development or such other person as Sponsor may from time to time designate in writing to University and the Principal Investigator ("Designated Representative").
4.2 During the Term of the Agreement, Sponsor's representatives may consult informally with University's representatives regarding the project, both personally and by telephone. Access to work carried on in University laboratories in the course of these investigations shall be entirely entirely. under the control of University personnel but shall be made available to Sponsor's representatives on a reasonable basis.
4.3 The Principal Investigator will make up to two (2) oral reports at reasonable intervals each year as requested by Sponsor's Designated Representative. In addition, at At the conclusion of each calendar quarter and each yearquarter, the Principal Investigator shall submit to Sponsor a written report summarizing the work. The Principal Investigator shall also submit a comprehensive final report within one hundred twenty (120) days of termination of the Agreement which shall contain, but which need not be limited to, the following information:: *#* CONFIDENTIAL TREATMENT REQUESTED
a. A summary of expenses of the Research Program; and,.
b. A report of the activities undertaken and accomplishments achieved by the University under the Research Program. [*#*] CONFIDENTIAL TREATMENT REQUESTED.
Appears in 1 contract
Samples: Exclusive Patent and Technology License Agreement (Myogen Inc)
CONSULTATION AND REPORTS. 4.1 Sponsor's designated representative for consultation and communications with the Principal Investigator shall be Sponsor's Vice President of Research and Development or such other person as Sponsor may from time to time designate in writing to University and the Principal Investigator ("Designated Representative").
4.2 During the Term of the Agreement, Sponsor's representatives may consult informally with University's representatives regarding the project, both personally and by telephone. Access to work carried on in University laboratories in the course of these investigations shall be entirely under the control of University personnel but shall be made available to Sponsor's representatives on a reasonable basis.
4.3 The Principal Investigator will make up to two (2) oral reports each year as requested by Sponsor's Designated Representative. In addition, at the conclusion of each calendar quarter and each year, the Principal Investigator shall submit to Sponsor a written report summarizing the work. The Principal Investigator shall also submit a comprehensive final report within one hundred twenty (120) days of termination of the Agreement which shall contain, but which need not be limited to, the following information:
a. A summary of expenses of the Research Program; and,[*#*]
b. A report of the activities undertaken and accomplishments achieved by the University under the Research Program. [*#*] [*#*] CONFIDENTIAL TREATMENT REQUESTED
Appears in 1 contract
Samples: Patent and Technology License Agreement (Myogen Inc)
CONSULTATION AND REPORTS. 4.1 Sponsor's designated representative for consultation and communications with the Principal Investigator shall be the Sponsor's Vice President of Research and Development or such other person as Sponsor may from time to time designate in writing to University and the Principal Investigator ("Designated Representative").
4.2 During the Term of the Agreement, Sponsor's representatives may consult informally with University's representatives regarding the project, both personally and by telephone. Access to work carried on in University laboratories in the course of these investigations shall be entirely entirely. under the control of University personnel but shall be made available to Sponsor's representatives on a reasonable basis.
4.3 The Principal Investigator will make up to two (2) oral reports at reasonable intervals each year as requested by Sponsor's Designated Representative. In addition, at At the conclusion of each calendar quarter and each yearquarter, the Principal Investigator shall submit to Sponsor a written report summarizing the work. The Principal Investigator shall also submit a comprehensive final report within one hundred twenty (120) days of termination of the Agreement which shall contain, but which need not be limited to, the following information:: *#* CONFIDENTIAL TREATMENT REQUESTED
a. A summary of expenses of the Research Program; and,
b. A report of the activities undertaken and accomplishments achieved by the University under the Research Program. [*#*] CONFIDENTIAL TREATMENT REQUESTED]
b. [*#*]
Appears in 1 contract
Samples: Exclusive Patent and Technology License Agreement (Myogen Inc)